AAPL311.00+1.62 (+0.52%) ▲|ABBV246.20+2.40 (+0.98%) ▲|ABT105.71+0.25 (+0.24%) ▲|ACN170.73+0.30 (+0.18%) ▲|ADBE259.32+1.83 (+0.71%) ▲|AMAT534.24-12.38 (-2.26%) ▼|AMD482.05-36.53 (-7.04%) ▼|AMGN407.83+17.81 (+4.57%) ▲|AMT168.07-7.18 (-4.10%) ▼|AMZN272.65-4.77 (-1.72%) ▼|AVGO418.28+0.12 (+0.03%) ▲|AXP348.99+2.28 (+0.66%) ▲|BA240.19+3.03 (+1.28%) ▲|BAC63.25+0.35 (+0.56%) ▲|BKNG207.02+12.75 (+6.56%) ▲|BLK1,133.58+2.45 (+0.22%) ▲|BMY63.63-2.26 (-3.43%) ▼|BNY158.74+1.92 (+1.22%) ▲|BRK-B518.85+1.63 (+0.32%) ▲|C137.64+0.77 (+0.56%) ▲|CAT871.08-5.46 (-0.62%) ▼|CL93.28+0.75 (+0.81%) ▲|CMCSA24.75-0.18 (-0.72%) ▼|COF221.63-0.28 (-0.13%) ▼|COP115.04-2.90 (-2.46%) ▼|COST941.99-5.86 (-0.62%) ▼|CRM192.98+1.99 (+1.04%) ▲|CSCO121.50-0.24 (-0.20%) ▼|CVS99.12-5.30 (-5.08%) ▼|CVX186.41-3.99 (-2.10%) ▼|DE612.00-5.37 (-0.87%) ▼|DHR199.66+4.88 (+2.51%) ▲|DIS101.76+3.58 (+3.65%) ▲|DUK123.34-0.93 (-0.75%) ▼|EMR162.47+3.63 (+2.29%) ▲|FDX310.72-2.62 (-0.84%) ▼|GD384.08-1.68 (-0.44%) ▼|GE381.22+3.94 (+1.04%) ▲|GEV1,017.96-0.57 (-0.06%) ▼|GILD131.76-3.49 (-2.58%) ▼|GM89.16+0.85 (+0.96%) ▲|GOOG360.13-15.22 (-4.05%) ▼|GOOGL362.43-15.22 (-4.03%) ▼|GS1,060.38+7.40 (+0.70%) ▲|HD353.14+4.90 (+1.41%) ▲|HON248.12-0.67 (-0.27%) ▼|IBM235.92+0.77 (+0.33%) ▲|INTC101.06+0.20 (+0.20%) ▲|INTU327.94+4.34 (+1.34%) ▲|ISRG375.20+6.94 (+1.88%) ▲|JNJ257.59+2.66 (+1.04%) ▲|JPM359.24+1.72 (+0.48%) ▲|KO86.83+0.27 (+0.31%) ▲|LIN491.05+6.41 (+1.32%) ▲|LLY1,169.86+54.18 (+4.86%) ▲|LMT577.60-11.73 (-1.99%) ▼|LOW219.94+1.86 (+0.85%) ▲|LRCX307.42-10.32 (-3.25%) ▼|MA570.48-0.62 (-0.11%) ▼|MCD274.00+5.66 (+2.11%) ▲|MDLZ62.60+0.52 (+0.84%) ▲|MDT85.99-0.21 (-0.24%) ▼|META588.77+0.83 (+0.14%) ▲|MMM182.08+0.63 (+0.35%) ▲|MO68.44+0.37 (+0.54%) ▲|MRK128.33+0.33 (+0.26%) ▲|MS218.27+1.23 (+0.57%) ▲|MSFT487.46-5.35 (-1.09%) ▼|MU893.19+0.52 (+0.06%) ▲|NEE85.91-1.29 (-1.48%) ▼|NFLX74.20+0.63 (+0.86%) ▲|NKE42.45+0.92 (+2.22%) ▲|NOW117.22-0.92 (-0.78%) ▼|NVDA219.22+7.28 (+3.43%) ▲|ORCL144.39-1.35 (-0.93%) ▼|PEP138.78-0.32 (-0.23%) ▼|PFE25.81+0.40 (+1.57%) ▲|PG146.80-1.21 (-0.82%) ▼|PLTR158.43-4.23 (-2.60%) ▼|PM188.93+2.02 (+1.08%) ▲|QCOM157.53-5.14 (-3.16%) ▼|RTX222.31+4.38 (+2.01%) ▲|SBUX106.00+1.03 (+0.98%) ▲|SCHW108.02+1.67 (+1.57%) ▲|SO93.10-0.15 (-0.16%) ▼|SPG224.81-1.09 (-0.48%) ▼|T23.06-0.32 (-1.37%) ▼|TMO577.83+13.08 (+2.32%) ▲|TMUS173.46-3.75 (-2.12%) ▼|TSLA321.55-5.80 (-1.77%) ▼|TXN277.72-5.91 (-2.08%) ▼|UBER68.18-3.81 (-5.29%) ▼|UNH412.75+5.20 (+1.28%) ▲|UNP295.54-0.81 (-0.27%) ▼|UPS107.70-1.41 (-1.29%) ▼|USB64.21-0.02 (-0.03%) ▼|V368.54-1.05 (-0.28%) ▼|VZ46.47-0.41 (-0.87%) ▼|WFC89.17+0.78 (+0.88%) ▲|WMT112.34+0.79 (+0.71%) ▲|XOM151.63-2.33 (-1.51%) ▼|AAPL311.00+1.62 (+0.52%) ▲|ABBV246.20+2.40 (+0.98%) ▲|ABT105.71+0.25 (+0.24%) ▲|ACN170.73+0.30 (+0.18%) ▲|ADBE259.32+1.83 (+0.71%) ▲|AMAT534.24-12.38 (-2.26%) ▼|AMD482.05-36.53 (-7.04%) ▼|AMGN407.83+17.81 (+4.57%) ▲|AMT168.07-7.18 (-4.10%) ▼|AMZN272.65-4.77 (-1.72%) ▼|AVGO418.28+0.12 (+0.03%) ▲|AXP348.99+2.28 (+0.66%) ▲|BA240.19+3.03 (+1.28%) ▲|BAC63.25+0.35 (+0.56%) ▲|BKNG207.02+12.75 (+6.56%) ▲|BLK1,133.58+2.45 (+0.22%) ▲|BMY63.63-2.26 (-3.43%) ▼|BNY158.74+1.92 (+1.22%) ▲|BRK-B518.85+1.63 (+0.32%) ▲|C137.64+0.77 (+0.56%) ▲|CAT871.08-5.46 (-0.62%) ▼|CL93.28+0.75 (+0.81%) ▲|CMCSA24.75-0.18 (-0.72%) ▼|COF221.63-0.28 (-0.13%) ▼|COP115.04-2.90 (-2.46%) ▼|COST941.99-5.86 (-0.62%) ▼|CRM192.98+1.99 (+1.04%) ▲|CSCO121.50-0.24 (-0.20%) ▼|CVS99.12-5.30 (-5.08%) ▼|CVX186.41-3.99 (-2.10%) ▼|DE612.00-5.37 (-0.87%) ▼|DHR199.66+4.88 (+2.51%) ▲|DIS101.76+3.58 (+3.65%) ▲|DUK123.34-0.93 (-0.75%) ▼|EMR162.47+3.63 (+2.29%) ▲|FDX310.72-2.62 (-0.84%) ▼|GD384.08-1.68 (-0.44%) ▼|GE381.22+3.94 (+1.04%) ▲|GEV1,017.96-0.57 (-0.06%) ▼|GILD131.76-3.49 (-2.58%) ▼|GM89.16+0.85 (+0.96%) ▲|GOOG360.13-15.22 (-4.05%) ▼|GOOGL362.43-15.22 (-4.03%) ▼|GS1,060.38+7.40 (+0.70%) ▲|HD353.14+4.90 (+1.41%) ▲|HON248.12-0.67 (-0.27%) ▼|IBM235.92+0.77 (+0.33%) ▲|INTC101.06+0.20 (+0.20%) ▲|INTU327.94+4.34 (+1.34%) ▲|ISRG375.20+6.94 (+1.88%) ▲|JNJ257.59+2.66 (+1.04%) ▲|JPM359.24+1.72 (+0.48%) ▲|KO86.83+0.27 (+0.31%) ▲|LIN491.05+6.41 (+1.32%) ▲|LLY1,169.86+54.18 (+4.86%) ▲|LMT577.60-11.73 (-1.99%) ▼|LOW219.94+1.86 (+0.85%) ▲|LRCX307.42-10.32 (-3.25%) ▼|MA570.48-0.62 (-0.11%) ▼|MCD274.00+5.66 (+2.11%) ▲|MDLZ62.60+0.52 (+0.84%) ▲|MDT85.99-0.21 (-0.24%) ▼|META588.77+0.83 (+0.14%) ▲|MMM182.08+0.63 (+0.35%) ▲|MO68.44+0.37 (+0.54%) ▲|MRK128.33+0.33 (+0.26%) ▲|MS218.27+1.23 (+0.57%) ▲|MSFT487.46-5.35 (-1.09%) ▼|MU893.19+0.52 (+0.06%) ▲|NEE85.91-1.29 (-1.48%) ▼|NFLX74.20+0.63 (+0.86%) ▲|NKE42.45+0.92 (+2.22%) ▲|NOW117.22-0.92 (-0.78%) ▼|NVDA219.22+7.28 (+3.43%) ▲|ORCL144.39-1.35 (-0.93%) ▼|PEP138.78-0.32 (-0.23%) ▼|PFE25.81+0.40 (+1.57%) ▲|PG146.80-1.21 (-0.82%) ▼|PLTR158.43-4.23 (-2.60%) ▼|PM188.93+2.02 (+1.08%) ▲|QCOM157.53-5.14 (-3.16%) ▼|RTX222.31+4.38 (+2.01%) ▲|SBUX106.00+1.03 (+0.98%) ▲|SCHW108.02+1.67 (+1.57%) ▲|SO93.10-0.15 (-0.16%) ▼|SPG224.81-1.09 (-0.48%) ▼|T23.06-0.32 (-1.37%) ▼|TMO577.83+13.08 (+2.32%) ▲|TMUS173.46-3.75 (-2.12%) ▼|TSLA321.55-5.80 (-1.77%) ▼|TXN277.72-5.91 (-2.08%) ▼|UBER68.18-3.81 (-5.29%) ▼|UNH412.75+5.20 (+1.28%) ▲|UNP295.54-0.81 (-0.27%) ▼|UPS107.70-1.41 (-1.29%) ▼|USB64.21-0.02 (-0.03%) ▼|V368.54-1.05 (-0.28%) ▼|VZ46.47-0.41 (-0.87%) ▼|WFC89.17+0.78 (+0.88%) ▲|WMT112.34+0.79 (+0.71%) ▲|XOM151.63-2.33 (-1.51%) ▼|
26.2 C
New York
Wednesday, August 5, 2026

Tag: optic nerve

newssourceFORcompanyinformationcontent1releasesmarket

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding memorandum of understanding (the “MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the “Definitive Agreement”) with ExoLyra LLC, which operates as an arm’s length third party (“ExoLyra”).

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Myra Vision Secures FDA Approval to Initiate US IDE Study in Glaucoma

The ADAPT study will evaluate the safety and effectiveness of the company's Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System CAMPBELL, Calif., Aug. 12, 2025 /PRNewswire/...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOptic nerve

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers